Evofem Biosciences, Inc. (EVFM)
0.0071
0.00 (0.00%)
USD |
OTCM |
Sep 08, 16:00
Evofem Biosciences Profit Margin (Quarterly) : -419.1% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -419.1% |
| March 31, 2026 | -607.9% |
| December 31, 2025 | 29.16% |
| September 30, 2025 | -31.68% |
| June 30, 2025 | -36.97% |
| March 31, 2025 | |
| December 31, 2024 | -42.75% |
| September 30, 2024 | -52.60% |
| June 30, 2024 | 32.48% |
| March 31, 2024 | -133.5% |
| December 31, 2023 | -43.69% |
| September 30, 2023 |
| Date | Value |
|---|---|
| June 30, 2023 | -348.2% |
| March 31, 2023 | -40.52% |
| December 31, 2022 | -4.61K% |
| September 30, 2022 | |
| June 30, 2022 | -2.09K% |
| March 31, 2022 | -750.1% |
| December 31, 2021 | -1.44K% |
| September 30, 2021 | -4.33K% |
| June 30, 2021 | -1.80K% |
| March 31, 2021 | -4.18K% |
| December 31, 2020 | -24.17K% |
| September 30, 2020 | -10.76K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 8.65% |
| Corcept Therapeutics, Inc. | 16.45% |
| Veru, Inc. | -- |
| Johnson & Johnson | 21.86% |
| Eli Lilly & Co. | 30.88% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -120.5% |
| Gross Profit Margin (Quarterly) | 80.06% |
| Operating Margin (Quarterly) | -94.53% |
| Return on Net Operating Assets | -138.7% |